Maravai LifeSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Updates 2022 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Maravai LifeScience Holdings Inc. (MRVI) PT Lowered to $45 at Stifel
February 24, 2022 7:14 AM ESTStifel analyst Daniel Arias lowered the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $45.00 (from $56.00) while maintaining a Buy rating.
The analyst commented, "MRVI posted a solid top- and bottom-line beat driven by strength in CleanCap. Along with earnings, management provided... More
Maravai LifeSciences (MRVI) Tops Q4 EPS by 7c; Guides Higher
February 23, 2022 4:57 PM ESTMaravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of $0.45, $0.07 better than the analyst estimate of $0.38. Revenue for the quarter came in at $228.4 million versus the consensus estimate of $208.09 million.
GUIDANCE:
Maravai LifeSciences sees FY2022 EPS of $1.70-$1.84, versus the consensus of $1.54.... More
